Cowen raises PTC Therapeutics stock price target to $50
Investors and market watchers will likely monitor PTC Therapeutics (NASDAQ:PTCT) closely to see if the company's performance aligns with Cowen's projections and to gauge the potential impact of this ...
Biogen (BIIB) Gets a Buy from RBC Capital
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of “Hold” from Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus rating of “Hold” from the fifteen research ...
hdbuzz.net2d
Huntington’s Disease Clinical Expert Prof. Ed Wild Shares Hopeful View For 2025
The HDBuzz team caught up with editor emeritus and Huntington's disease specialist, Prof Ed Wild to hear his thoughts on what ...
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment
Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical ...
Analysts Set Expectations for PTCT FY2025 Earnings
Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for PTC Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the ...
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), COMPASS Pathways (CMPS) and Cogstate Ltd (OtherCOGZF)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PTC Therapeutics (PTCT – Research Report), ...